State Science and Technology Grants

The Clean Fleet Enterprise’s (CFE) Clean Fleet Vehicle and Technology grant program is a statewide competitive application process for fleet vehicles and other clean fleet technology. Donor Name: Colorado Department of Public Health & Environment State: Colorado County: All Counties Type of Grant: Grant Deadline: 06/21/2024 Size of the Grant: Not Available Grant Duration: Grant Duration Not Mentioned Details: Fleets will provide background information on their current fleet make-up, indicate the level of planning that has occurred for fleet transition, and provide information on vehicles and/or technology the fleet plans to acquire. In general, a successful applicant will convey an understanding of the grant program criteria, their preparedness to manage a complex and long- term fleet transition project, and their commitment to maintaining awarded vehicles in everyday fleet operations. Program Requirements  Requested vehicles must be domiciled in and operated from a site in the state of Colorado with a large percentage of their travel within the state. Requested vehicles should be owned and operated by the fleet or individual fleet owner applying for funding. In cases where a third-party, who will not operate the vehicles directly, applies for funding, information on ownership of the vehicles must be included with the application materials for consideration. Applicants must operate awarded vehicles per the terms and conditions provided by the state. Applicants are required to provide proof they are currently registered and in good standing with the Colorado Secretary of State. Business entities outside of Colorado must review and, where applicable, file a Statement of Foreign Entity Authority (SOFEA) with the Colorado Secretary of State before submitting their application. Requested vehicles must be insured and authorized for use in the state of Colorado. Requested new vehicles must be procured in their original manufactured condition from a retail business or dealership, with no previous ownership. Used and/or demonstration vehicles are not eligible for funding through the Clean Fleet Enterprise. Upon award, applicants must agree to share vehicle operational data with the Clean Fleet Enterprise. Additional information on data collection will be provided on the program webpage. Applicants will be required to provide vehicle information with the Clean Fleet Enterprise. Fleets must notify the Clean Fleet Enterprise ahead of any intent to move awarded vehicles out of Colorado. Application submissions may not include confidential or trade-secret information. If an applicant believes information required to complete the application is confidential or trade-secret, they must prepare a redacted copy for submission and indicate such in the document title. The Clean Fleet Enterprise reserves the right to return applications that include confidential or trade-secret information. For more information, visit DPHE.

The Outdoor Recreation, Parks & Trails (ORPT) Program, formerly known as the Delaware Land and Water Conservation Trust Fund (DTF), is a matching grant program assisting with public park land acquisition and outdoor recreation facility development in Delaware. Donor Name: Delaware Department of Natural Resources and Environmental Control State: Delaware County: All Counties Type of Grant: Grant | Matching Grants Deadline: 05/15/2024 Size of the Grant: Not Available Grant Duration: Grant Duration Not Mentioned Details: Eligible Projects ORPT grant assistance is available for the following types of projects: Fee simple acquisition of parkland, open space, or conservation areas Purchase of development rights for public parkland, open space, or conservation areas Replacement of outdated and unsafe outdoor facilities Outdoor recreation facility engineering and design Outdoor recreation facility construction for example: Athletic fields and courts Playground equipment Swimming pools Picnic tables and pavilions Park maps for information boards or kiosks Park infrastructure such as entrance roads, parking, restrooms, and way finding Municipal or countywide park/open space comprehensive plans Universal accessibility upgrades to outdoor recreation facilities Professional services for park master planning Eligibility Criteria County and municipal governments and park districts may request and receive ORPT grant assistance. Projects sponsored by municipalities and counties may receive up to fifty percent (50%) in ORPT assistance of an approved project’s total costs; park districts, municipalities that have not received ORPT funds in the past, and projects located in or serving Census Tracts identified as highest vulnerability by the CDC Social Vulnerability Index (SVI score range 0.75 – 1.00) are eligible to receive up to seventy-five percent (75%) in ORPT assistance of an approved project’s total costs. The Sponsor may obtain its share through partnerships with other governmental agencies, non-profit organizations, and other non-traditional recreation providers. Partnerships with other agencies and organizations are encouraged however, only the municipalities and counties are eligible to apply for ORPT assistance. For more information, visit DNREC.

This funding opportunity provides up to $75,000 to researchers in Delaware to develop innovative ideas into marketable products or services, fostering the growth of new businesses and high-tech jobs in the state.

The FY23-24 Drone Replacement Program is funded by the Florida Department of Law Enforcement (FDLE) to assist agencies in replacing non-compliant drones with those from approved manufacturers. The program was established following the 2022 amendment of Section 934.50, Florida Statutes, mandating agencies using non-compliant drones to replace them by specific deadlines. Eligible agencies will receive funds based on the initial purchase price and total flight hours of the non-compliant drones, following a detailed depreciation schedule. Recipients are required to relinquish the non-compliant drones in working condition to FDLE, which will then be analyzed by the Florida Center for Cybersecurity at the University of South Florida. Criminal Justice Information Data Security: Acceptance of this award, constitutes understanding that transmission of Criminal Justice Information (CJI) between locations must be encrypted to conform to the Federal Bureau of Investigation (FBI) Criminal Justice Information Services (CJIS) Security Policy.

This funding opportunity supports collaborative bioscience research projects between Delaware academic institutions and businesses, aimed at fostering innovation and economic growth in the state.

ARC supports bioscience research projects that involve collaboration between Delaware academic institutions and business partners. It is designed to enhance applied research collaborations, and single PI proposals may request up to $100,000; multi-PI proposals may request up to $150,000 for one year. The program requires matching funds from the collaborating industry partner. Grant renewed every year.

The Nebraska SBIR/STTR Initiative provides financial assistance to small businesses in Nebraska participating in the federal SBIR/STTR programs. This state initiative offers Phase 0 assistance to help businesses apply for federal Phase 1 funding and matching funds for successful Phase 1 and Phase 2 federal awards. The initiative aims to promote innovation and technology transfer among small businesses in Nebraska, with a total fund availability of up to $6 million per year. Grant renewed every year. Grant Annual opening/closing deadline: July 1st to June 30th

This funding opportunity supports innovative bioscience research projects in Delaware that have the potential for significant economic impact, targeting researchers and businesses in the developmental stage.

EPoC – Entrepreneurial Proof of Concept o Supports proof of concept research towards establishing a new Delaware-based business by the end of the grant period. o Up to $75,000 for 1 year . Proposal must be submitted as a single electronic PDF document at the link provided on the CAT website https://cat.dbi.udel.edu. Please note that submission and award processes have changed.Proposal must be submitted as a single electronic PDF document at the link provided on the CAT website https://cat.dbi.udel.edu. Please note that submission and award processes have changed.

iHIT – Ideas – High-return, Innovative, Transformative o Supports ideas in bioscience research that are in the development stage and promise to have a high economic return for innovative and transformative research projects. o This mechanism intends to support applicants to develop novel lines of multidisciplinary research different from their ongoing research. o Up to $75,000 for 1 year.Proposal must be submitted as a single electronic PDF document at the link provided on the CAT website https://cat.dbi.udel.edu. Please note that submission and award processes have changed.

TAP provides Delaware bioscience businesses access to high-end research technologies at reduced rates. Eligible facilities include Bioimaging, DNA Sequencing & Genotyping, Bioinformatics, NMR, and Mass Spectrometry. This program supports the technological advancement of Delaware's bioscience sector by making cutting-edge resources more accessible, with funding up to $5,000 per year per core facility.

The Arkansas Department of Environmental Quality runs an annual Electronic Waste Grants. This initiative aims to address electronic waste through projects focused on collection, transportation, processing, recycling, demanufacturing, and innovative approaches to disposal. Eligible projects are evaluated based on the sustainability and impact of their e-waste recovery efforts, including the minimization of e-waste volumes, job creation in Arkansas, and the effectiveness of investment in the projects. Eligible applicants include a wide range of entities within Arkansas, such as private industries, educational institutions, governmental bodies, non-profits, and regional solid waste management boards. This program operates on a reimbursement basis. Grant renewed every year. Grant Annual opening/closing deadline: January 1st to June 1st

Supports the construction, purchase, expansion, or upgrade of workforce or training-related infrastructure to better meet the needs of the offshore wind industry.

The Tier 3 Clinical/Translational Research Grant is designed for advanced research projects that are concurrently applying for or have funding from federal or industry sources. This grant requires published preliminary data and offers up to $500,000 over three years with an additional two-year no-cost extension.

This grant option, part of the Minnesota Spinal Cord Injury and Traumatic Brain Injury Research Grant Program, aims to support early-stage research into innovative treatments and rehabilitative techniques for spinal cord and traumatic brain injuries. The Tier 1 Pilot Project Grant does not require preliminary data but encourages it, reflecting early investment as researchers prepare to seek larger grants. The funding amount can reach up to $125,000 for a project duration of two years with an additional one-year no-cost extension.

This grant option, part of the Minnesota Spinal Cord Injury and Traumatic Brain Injury Research Grant Program, aims to support early-stage research into innovative treatments and rehabilitative techniques for spinal cord and traumatic brain injuries. The Tier 1 Pilot Project Grant does not require preliminary data but encourages it, reflecting early investment as researchers prepare to seek larger grants. The funding amount can reach up to $125,000 for a project duration of two years with an additional one-year no-cost extension.

Funding available through this RFA supports company formation, as well as early research and development of novel oncology therapeutics, devices, treatment-oriented information technology products, diagnostics, or tools. The objective of the SEED Award program is to start with an interesting technology and to progress it toward a commercially viable business opportunity, i.e., make it more attractive to private funding agents. Typically, applicants have completed the following activities: Identified a novel therapeutic, diagnostic technology, or clinical tool and shown a biological effect Conducted preliminary safety and toxicology testing (in the case of therapeutic agents) Shown the product can be manufactured at small scale or as a prototype Assessed the business opportunity and organized a business plan that begins to address key issues (clinical utility, target market, financial plan, IP strategy, technical challenges, etc.) and lays out a preliminary development plan (formulation, toxicology, scale up, IND-enabling studies, phase 1 clinical trials, regulatory pathway, etc.). Established a company

Funding available through this RFA supports the ongoing research and development of diagnostic tests and devices to treat, detect, diagnose, monitor, and assist in the treatment of cancer. Relevant areas include: Devices and assays for cancer detection, diagnosis, prognosis, monitoring, treatment and prediction of response or resistance to treatment Markers for cancer prevention and control, companion diagnostic to a therapy Development of diagnostic tests to distinguish high-risk early lesions Generally, at the time that an applicant applies to CPRIT pursuant to this RFA, the company has developed a commercial prototype of the device or a pictorial representation of the functional components/elements of the device. With respect to diagnostics, the company has developed assays that work on human samples and whose importance is well justified for development into clinical assays. The applicant should be working toward submitting an Investigational Device Exemption (IDE) or a 510(k) or Premarketing Approval (PMA) and is typically within one year from filing an IDE (or later stage work.) Potential applicants that are not at or near this stage of product development should consider applying for a Texas Seed Company Award. With appropriate justification, companies may use CPRIT funds to support studies that establish preclinical proof of concept, product validation, design, production, manufacturing and development, and clinical studies demonstrating safety and efficacy.

Funding available through this RFA supports the ongoing research and development of innovative products, services, and infrastructure with significant potential impact on patient care. Generally, at this stage, the company has identified and characterized a lead compound; demonstrated efficacy in multiple translationally relevant animal models; completed pilot/dose ranging toxicology studies; determined the feasibility of a scalable, GMP compliant manufacturing process, including release assays; and identified a prototype formulation suitable for further development. The applicant is typically within one year from filing an IND/IDE or already in Phase 1. With appropriate justification, companies may use CPRIT funds to support the following: Studies that establish preclinical proof of concept (safety and efficacy) CMC/manufacturing development GLP safety studies to support INDs Phase 1 in humans to establish safety and a recommended dose for phase 2 Phase 2 studies to determine safety and efficacy in initial targeted patient population

Funding available through this RFA supports the ongoing research and development of new and emerging technologies for the detection, diagnosis, prognosis, monitoring, or treatment of cancer. CPRIT created this RFA to fund new and emerging technology projects that do not easily fit into any of the three other CPRIT Product Development Research RFAs. Proposals may include, but are not limited to, bioinformatics, artificial intelligence, production of radionuclides or their precursors, manufacture of cell-based therapies, processes to improve the quality of the samples used for cancer research or clinical care, and biomanufacturing of therapeutics. With appropriate justification, companies may use CPRIT funds to support studies that establish preclinical proof of concept, product validation, design, production, manufacturing and development, and clinical studies demonstrating safety and efficacy.